样式: 排序: IF: - GO 导出 标记为已读
-
Long‐term efficacy and safety of tailored immunosuppressive therapy in immune‐mediated biopsy‐proven myocarditis: A propensity‐weighted study Eur. J. Heart Fail. (IF 18.2) Pub Date : 2024-04-17 Alida Linda Patrizia Caforio, Andrea Silvio Giordani, Anna Baritussio, Davide Marcolongo, Cristina Vicenzetto, Giuseppe Tarantini, Massimo Napodano, Giuseppe Toscano, Dario Gregori, Gloria Brigiari, Patrizia Bartolotta, Elisa Carturan, Monica De Gaspari, Stefania Rizzo, Cristina Basso, Sabino Iliceto, Renzo Marcolongo
AimsStandardized immunosuppressive therapy (IS) had been previously investigated in biopsy‐proven (BP) lymphocytic myocarditis with heart failure (HF). This study evaluated efficacy and safety of tailored IS in BP immune‐mediated myocarditis, irrespective of histology and clinical presentation.Methods and resultsConsecutive BP myocarditis patients treated with long‐term tailored IS on top of optimal
-
Time to clinical benefit with sotagliflozin in patients with type 2 diabetes and chronic kidney disease: Insights from the SCORED randomized trial Eur. J. Heart Fail. (IF 18.2) Pub Date : 2024-04-17 Rahul Aggarwal, Deepak L. Bhatt, Michael Szarek, Lawrence A. Leiter, Christopher P. Cannon, Renato D. Lopes, Michael J Davies, Phillip Banks, Bertram Pitt, Ph. Gabriel Steg
-
Mitral regurgitation in heart failure with preserved ejection fraction: The interplay of valve, ventricle, and atrium Eur. J. Heart Fail. (IF 18.2) Pub Date : 2024-04-17 Sebastiaan Dhont, Gitte van den Acker, Tim van Loon, Frederik H. Verbrugge, Jan Verwerft, Sébastien Deferm, Timothy W. Churchill, Wilfried Mullens, Joost Lumens, Philippe B. Bertrand
Mitral regurgitation (MR) is highly prevalent among patients with heart failure and preserved ejection fraction (HFpEF). Despite this combination being closely associated with unfavourable outcomes, it remains relatively understudied. This is partly due to the inherent heterogeneity of patients with HFpEF. To address this gap, dissecting HFpEF into mechanism‐based phenotypes may offer a promising avenue
-
The changing landscape of heart failure treatment in transthyretin amyloid cardiomyopathy: Is the time ripe for clinical use of sodium–glucose cotransporter 2 inhibitors? Eur. J. Heart Fail. (IF 18.2) Pub Date : 2024-04-16 Aldostefano Porcari, Marianna Fontana
-
Reporting quality of heart failure randomized controlled trials 2000–2020: Temporal trends in adherence to CONSORT criteria Eur. J. Heart Fail. (IF 18.2) Pub Date : 2024-04-16 Mohamed B. Jalloh, Veronica A. Bot, Cristiana Z. Borjaille, Lehana Thabane, Guowei Li, Javed Butler, Faiez Zannad, Christopher B. Granger, Harriette G.C. Van Spall
-
Serum metabolomics improves risk stratification for incident heart failure Eur. J. Heart Fail. (IF 18.2) Pub Date : 2024-04-16 Rafael R. Oexner, Hyunchan Ahn, Konstantinos Theofilatos, Ravi A. Shah, Robin Schmitt, Philip Chowienczyk, Anna Zoccarato, Ajay M. Shah
-
Baroreflex activation therapy in patients with heart failure and a reduced ejection fraction: Long‐term outcomes Eur. J. Heart Fail. (IF 18.2) Pub Date : 2024-04-12 Michael R. Zile, JoAnn Lindenfeld, Fred A. Weaver, Faiez Zannad, Elizabeth Galle, Tyson Rogers, William T. Abraham
AimsCarotid baroreflex activation therapy (BAT) restores baroreflex sensitivity and modulates the imbalance in cardiac autonomic function in patients with heart failure with reduced ejection fraction (HFrEF). We tested the hypothesis that treatment with BAT significantly reduces cardiovascular mortality and heart failure morbidity and provides long‐term safety and sustainable symptomatic improvement
-
Reply to ‘The pharmacist ally in heart failure: Useful when involved’ Eur. J. Heart Fail. (IF 18.2) Pub Date : 2024-04-12 Craig J. Beavers, Deepak L. Bhatt, Gad Gotter
-
Dietary sodium and fluid intake in heart failure. A clinical consensus statement of the Heart Failure Association of the ESC Eur. J. Heart Fail. (IF 18.2) Pub Date : 2024-04-12 Wilfried Mullens, Kevin Damman, Sebastiaan Dhont, Debasish Banerjee, Antoni Bayes‐Genis, Antonio Cannata, Ovidiu Chioncel, Maja Cikes, Justin Ezekowitz, Andreas J. Flammer, Pieter Martens, Alexandre Mebazaa, Robert J. Mentz, Òscar Miró, Brenda Moura, Julio Nunez, Jozine M. Ter Maaten, Jeffrey Testani, Roland van Kimmenade, Frederik H. Verbrugge, Marco Metra, Giuseppe M.C. Rosano, Gerasimos Filippatos
Sodium and fluid restriction has traditionally been advocated in patients with heart failure (HF) due to their sodium and water avid state. However, most evidence regarding the altered sodium handling, fluid homeostasis and congestion‐related signs and symptoms in patients with HF originates from untreated patient cohorts and physiological investigations. Recent data challenge the beneficial role of
-
Left atrial to coronary sinus shunting for treatment of heart failure with mildly reduced or preserved ejection fraction: The ALT FLOW Early Feasibility Study 1‐year results Eur. J. Heart Fail. (IF 18.2) Pub Date : 2024-04-12 Marcus A. Urey, Benjamin Hibbert, Ulrich Jorde, Peter Eckman, Trevor Simard, Marino Labinaz, Babak Nazer, Mark Wiley, Bhanu Gupta, Andrew Sauer, Hirak Shah, Paul Sorajja, Andres M. Pineda, Emil Missov, Ehtisham Mahmud, Rami Kahwash, Scott Lilly, Azeem Latib, Sandhya Murthy, Neil Fam, Santiago Garcia, Eugene S. Chung, Liviu Klein, Richard Cheng, Brian A. Houston, Nicholas S. Amoroso, Lee Chang, Sameer
AimsPatients with heart failure and mildly reduced or preserved ejection fraction have limited therapeutic options. The ALT‐FLOW Early Feasibility Study evaluated safety, haemodynamics and outcomes for the APTURE transcatheter shunt system, a novel left atrium to coronary sinus shunt in these patients.Methods and resultsSafety and shunt implantation success was evaluated for all 116 enrolled patients
-
Impact of guideline‐directed medical therapy on systolic blood pressure and cardiovascular outcomes in patients with heart failure and low blood pressure: A systematic review and meta‐analysis Eur. J. Heart Fail. (IF 18.2) Pub Date : 2024-04-12 Jingwei Li, Yunlong Chen, Yi Wang, Xiaoyan Liu, Ping Li, Yongming He, Yang Hao, Lan Huang, Jun Jin, Jiang Wang, Craig Anderson
AimsExisting research indicates that patients with heart failure (HF) may have restricted access to guideline‐directed medical therapy (GDMT) when their blood pressure (BP) is comparatively low. However, recent clinical trials suggest that HF patients with low BP could still benefit from certain HF medications, which have a minimal impact on BP. This systematic review and meta‐analysis was conducted
-
Heart failure and respiratory tract infection: Cause and consequence of acute decompensation? Eur. J. Heart Fail. (IF 18.2) Pub Date : 2024-04-12 Bettina Heidecker, Matteo Pagnesi, Thomas F. Lüscher
-
Cause‐specific death in heart failure across the ejection fraction spectrum: A comprehensive assessment of over 100 000 patients in the Swedish Heart Failure Registry Eur. J. Heart Fail. (IF 18.2) Pub Date : 2024-04-12 Camilla Settergren, Lina Benson, Angiza Shahim, Ulf Dahlström, Tonje Thorvaldsen, Gianluigi Savarese, Lars H. Lund, Bahira Shahim
AimTo assess cause‐specific death in patients with heart failure with preserved, mildly reduced, and reduced ejection fraction (HFpEF, HFmrEF, and HFrEF).Methods and resultsData were analysed from the Swedish Heart Failure Registry (SwedeHF) and the National Patient Register of patients enrolled in SwedeHF 2000–2021. Cox proportional hazards regression models were performed and adjusted for age, sex
-
Multimorbidity in the era of increasing life expectancy and aging population Eur. J. Heart Fail. (IF 18.2) Pub Date : 2024-04-11 Nikhil Patel, Joseph Yeboah
-
-
Supplement Article Eur. J. Heart Fail. (IF 18.2) Pub Date : 2024-04-10
Welcome Address Dear Colleagues, It was with great pleasure that we welcomed you all for the 18th Annual Winter Research Meeting on Translational Heart Failure, organised by the Heart Failure Association (HFA) in collaboration with the Working Group in Myocardial Function of the European Society of Cardiology. The HFA Winter Research Meeting has been a long-standing tradition and has emerged as the
-
Effects of sacubitril/valsartan according to polypharmacy status in PARAGON‐HF Eur. J. Heart Fail. (IF 18.2) Pub Date : 2024-04-08 Shingo Matsumoto, Mingming Yang, Li Shen, Alasdair Henderson, Brian L. Claggett, Akshay S. Desai, Martin Lefkowitz, Jean L. Rouleau, Orly Vardeny, Michael R. Zile, Pardeep S. Jhund, Muthiah Vaduganathan, Scott D. Solomon, John J.V. McMurray
-
Insulin‐like growth factor binding protein‐7 concentrations in chronic heart failure: Results from the EMPEROR programme Eur. J. Heart Fail. (IF 18.2) Pub Date : 2024-04-08 João Pedro Ferreira, Milton Packer, Naveed Sattar, Javed Butler, Sandra González Maldonado, Marina Panova‐Noeva, Mikhail Sumin, Serge Masson, Stuart J. Pocock, Stefan D. Anker, Faiez Zannad, James L. Januzzi
AimsInsulin‐like growth factor binding protein‐7 (IGFBP7) is a biomarker of tissue senescence with a role in cardio‐renal pathophysiology. The role of IGFBP7 as a prognostic biomarker across the full ejection fraction (EF) spectrum of heart failure (HF) remains less well understood. We examined associations between IGFBP7 and risk of cardio‐renal outcomes regardless of EF and the effect of empagliflozin
-
Comparative effectiveness of sacubitril/valsartan versus angiotensin‐converting enzyme inhibitors/angiotensin receptor blockers in patients with de novo heart failure with mildly reduced and preserved ejection fraction Eur. J. Heart Fail. (IF 18.2) Pub Date : 2024-04-07 Ankeet S. Bhatt, Muthiah Vaduganathan, Barada Prasad Jena, Sylwia Suminska, Carlos Eid, Rahul Khairnar, Gabriella Farries, Michele Senni
-
Incidence and predictors of heart failure with reduced and preserved ejection fraction after ST‐elevation myocardial infarction in the contemporary era of early percutaneous coronary intervention Eur. J. Heart Fail. (IF 18.2) Pub Date : 2024-04-05 Chris Lenselink, Kim W.L.M. Ricken, Hilde E. Groot, Tijs J. de Bruijne, Tom Hendriks, Pim van der Harst, Adriaan A. Voors, Erik Lipsic
-
Treatment effects of empagliflozin in hospitalized heart failure patients across the range of left ventricular ejection fraction – Results from the EMPULSE trial Eur. J. Heart Fail. (IF 18.2) Pub Date : 2024-04-04 Jasper Tromp, Mikhail N. Kosiborod, Christiane E. Angermann, Sean P. Collins, John R. Teerlink, Piotr Ponikowski, Jan Biegus, João Pedro Ferreira, Michael E. Nassif, Mitchell A. Psotka, Martina Brueckmann, Jonathan P Blatchford, Dominik Steubl, Adriaan A. Voors
AimThe EMPULSE (EMPagliflozin in patients hospitalised with acUte heart faiLure who have been StabilizEd) trial showed that, compared to placebo, the sodium–glucose cotransporter 2 inhibitor empagliflozin (10 mg/day) improved clinical outcomes of patients hospitalized for acute heart failure (HF). We investigated whether efficacy and safety of empagliflozin were consistent across the spectrum of left
-
Congestion patterns in severe tricuspid regurgitation and transcatheter treatment: Insights from a multicentre registry Eur. J. Heart Fail. (IF 18.2) Pub Date : 2024-04-04 Karl‐Philipp Rommel, Guillaume Bonnet, Vera Fortmeier, Lukas Stolz, Anne R. Schöber, Jennifer von Stein, Mohammad Kassar, Muhammed Gerçek, Sebastian Rosch, Thomas J. Stocker, Maria I. Körber, Karl‐Patrik Kresoja, Tanja K. Rudolph, Roman Pfister, Stephan Baldus, Stephan Windecker, Holger Thiele, Fabien Praz, Jörg Hausleiter, Volker Rudolph, Daniel Burkhoff, Philipp Lurz
-
Comorbidities and cardiac resynchronization therapy: Do we talk the talk or should we walk the walk? Eur. J. Heart Fail. (IF 18.2) Pub Date : 2024-04-02 Domenico D'Amario, Renzo Laborante, Pasquale Santangeli
-
Circulating levels of carbohydrate antigen 125 in chronic heart failure: Useful or futile? Eur. J. Heart Fail. (IF 18.2) Pub Date : 2024-04-02 Herminio Morillas, Julio Núñez, Pedro Moliner
-
Sodium–glucose cotransporter 2 inhibitors and skeletal muscle Eur. J. Heart Fail. (IF 18.2) Pub Date : 2024-04-02 Andrew J. Stewart Coats
-
Interatrial shunt therapy in advanced heart failure: Outcomes from the open‐label cohort of the RELIEVE‐HF trial Eur. J. Heart Fail. (IF 18.2) Pub Date : 2024-04-02 Josep Rodés‐Cabau, JoAnn Lindenfeld, William T. Abraham, Michael R. Zile, Saibal Kar, Antoni Bayés‐Genís, Neal Eigler, Richard Holcomb, Julio Núñez, Elizabeth Lee, Michal Laufer Perl, Gil Moravsky, Michael Pfeiffer, John Boehmer, John Gorcsan, Jeroen J. Bax, Stefan Anker, Gregg W. Stone
-
Impact of baseline kidney dysfunction on oral diuretic efficacy following hospitalization for heart failure – insights from TRANSFORM‐HF Eur. J. Heart Fail. (IF 18.2) Pub Date : 2024-04-01 Pieter Martens, Stephen J. Greene, Robert J. Mentz, Shuang Li, Daniel Wojdyla, Chris J. Kapelios, Wilfried Mullens, Michael E. Hall, Fassil Ketema, Dong‐Yun Kim, Eric L. Eisenstein, Kevin Anstrom, James C. Fang, Bertram Pitt, Eric J. Velazquez, W.H. Wilson Tang
-
Cost‐effectiveness of remote haemodynamic monitoring by an implantable pulmonary artery pressure monitoring sensor (CardioMEMS‐HF system) in chronic heart failure in the Netherlands Eur. J. Heart Fail. (IF 18.2) Pub Date : 2024-04-01 Hamraz Mokri, Pascal R.D. Clephas, Rudolf A. de Boer, Pieter van Baal, Jasper J. Brugts, Maureen P.M.H. Rutten‐van Mölken
AimsRemote haemodynamic monitoring with an implantable pulmonary artery (PA) sensor has been shown to reduce heart failure (HF) hospitalizations and improve quality of life. Cost‐effectiveness analyses studying the value of remote haemodynamic monitoring in a European healthcare system with a contemporary standard care group are lacking.Methods and resultsA Markov model was developed to estimate the
-
Body mass index and cardiorenal outcomes in the EMPEROR‐Preserved trial: Principal findings and meta‐analysis with the DELIVER trial Eur. J. Heart Fail. (IF 18.2) Pub Date : 2024-04-01 Naveed Sattar, Javed Butler, Matthew M.Y. Lee, Josephine Harrington, Abhinav Sharma, Faiez Zannad, Gerasimos Filippatos, Subodh Verma, James L. Januzzi, João Pedro Ferreira, Stuart J. Pocock, Egon Pfarr, Anne P. Ofstad, Martina Brueckmann, Milton Packer, Stefan D. Anker
-
Serial direct sodium removal in patients with heart failure and diuretic resistance Eur. J. Heart Fail. (IF 18.2) Pub Date : 2024-04-01 Veena S. Rao, Juan B. Ivey‐Miranda, Zachary L. Cox, Julieta Moreno‐Villagomez, Daniela Ramos‐Mastache, Daniel Neville, Natasha Balkcom, Jennifer L. Asher, Lavanya Bellumkonda, Tamar Bigvava, Tamaz Shaburishvili, Jozef Bartunek, F. Perry Wilson, Fredrick Finkelstein, Christopher Maulion, Jeffrey M. Turner, Jeffrey M. Testani
-
Proteomic profiles of left atrial volume and its influence on response to spironolactone: Findings from the HOMAGE trial and STANISLAS cohort Eur. J. Heart Fail. (IF 18.2) Pub Date : 2024-03-25 Masatake Kobayashi, João Pedro Ferreira, Duarte Kevin, Emmanuel Bresso, Olivier Huttin, Erwan Bozec, Hans-Peter Brunner La Rocca, Christian Delles, Andrew L. Clark, Frank Edelmann, Arantxa González, Stephane Heymans, Pierpaolo Pellicori, Johannes Petutschnigg, Job A.J. Verdonschot, Patrick Rossignol, John G.F. Cleland, Faiez Zannad, Nicolas Girerd
-
More than just a clinical syndrome: Biomarkers and echocardiography should be rapidly advised for anyone with suspected heart failure! Eur. J. Heart Fail. (IF 18.2) Pub Date : 2024-03-27 Erwan Donal, Louis Gegout, K. Charlotte Lee
-
-
The pharmacist ally in heart failure: Useful when involved. Letter regarding the article ‘Effective medications can work only in patients who take them: Implications for post‐acute heart failure care’ Eur. J. Heart Fail. (IF 18.2) Pub Date : 2024-03-26 Lorenz Van der Linden, Fatma Karapinar‐Carkıt, Paul Forsyth
-
Temporary mechanical circulatory support for cardiogenic shock: Definitive intervention or ancillary bridging therapy? Letter regarding the article ‘What about current recommendations for extracorporeal life support in acute myocardial infarction‐associated cardiogenic shock: Stay or go? or time to revise?’ Eur. J. Heart Fail. (IF 18.2) Pub Date : 2024-03-26 Jonathan R. Dalzell, Jane A. Cannon
-
Global longitudinal strain as a predictor of risk in patients with heart failure with preserved ejection fraction: A deserved role? Eur. J. Heart Fail. (IF 18.2) Pub Date : 2024-03-26 Francois Deharo, Julia Grapsa
-
Pre‐diagnostic free androgen and estradiol levels influence heart failure risk in both women and men: A prospective cohort study in the UK Biobank Eur. J. Heart Fail. (IF 18.2) Pub Date : 2024-03-26 Jungeun Lim, Maryam Hashemian, Batel Blechter, Véronique L. Roger, Jason Y.Y. Wong
-
Physician perceptions, attitudes, and strategies towards implementing guideline‐directed medical therapy in heart failure with reduced ejection fraction. A survey of the Heart Failure Association of the ESC and the ESC Council for Cardiology Practice Eur. J. Heart Fail. (IF 18.2) Pub Date : 2024-03-22 Gianluigi Savarese, Felix Lindberg, Ruxandra M. Christodorescu, Marc Ferrini, Thomas Kumler, Konstantinos Toutoutzas, Giuseppe Dattilo, Antoni Bayes‐Genis, Brenda Moura, Offer Amir, Mark C. Petrie, Petar Seferovic, Ovidiu Chioncel, Marco Metra, Andrew J.S. Coats, Giuseppe M.C. Rosano
-
Reply to ‘Breaking down peripartum cardiomyopathy: A learning adventure’ Eur. J. Heart Fail. (IF 18.2) Pub Date : 2024-03-22 Johann Bauersachs, Alice M Jackson, Karen Sliwa
-
Cost‐effectiveness of dapagliflozin for patients with heart failure across the spectrum of ejection fraction: A pooled analysis of DAPA‐HF and DELIVER data Eur. J. Heart Fail. (IF 18.2) Pub Date : 2024-03-21 Jason A. Davis, David Booth, Phil McEwan, Scott D. Solomon, John J.V. McMurray, Rudolf A. de Boer, Josep Comin‐Colet, Erasmus Bachus, Jieling Chen
-
Moving theory and reality closer together in cardio‐oncology training Eur. J. Heart Fail. (IF 18.2) Pub Date : 2024-03-20 Kalliopi Keramida, Eric H Yang, Anita Deswal
-
Renal perturbations with sodium–glucose cotransporter 2 inhibitor in heart failure with preserved ejection fraction Eur. J. Heart Fail. (IF 18.2) Pub Date : 2024-03-19 Simon Vanhentenrijk, W.H. Wilson Tang
-
Dissecting the heart failure phenotype through phenomics Eur. J. Heart Fail. (IF 18.2) Pub Date : 2024-03-19 Giorgia Panichella, Daniela Tomasoni, Alberto Aimo
-
Sodium–glucose cotransporter 2 inhibitors for transthyretin amyloid cardiomyopathy: Analyses of short‐term efficacy and safety Eur. J. Heart Fail. (IF 18.2) Pub Date : 2024-03-16 Frederick M. Lang, Sergio Teruya, Ariel Weinsaft, Margaret Cuomo, Alfonsina Mirabal Santos, Ani Nalbandian, Dimitrios Bampatsias, Mathew S. Maurer
AimsDespite their potential, sodium–glucose cotransporter 2 inhibitors (SGLT2i) have not been well‐studied in transthyretin amyloid cardiomyopathy (ATTR‐CM) as randomized trials have excluded patients with this morbid disease. We performed a retrospective study assessing the short‐term efficacy and safety of SGLT2i in ATTR‐CM.Methods and resultsWe screened consecutive patients seen at a tertiary care
-
Dapagliflozin in patients with heart failure and previous myocardial infarction: A participant‐level pooled analysis of DAPA‐HF and DELIVER Eur. J. Heart Fail. (IF 18.2) Pub Date : 2024-03-15 Alexander Peikert, Muthiah Vaduganathan, Brian L. Claggett, Ian J. Kulac, Alberto Foà, Akshay S. Desai, Pardeep S. Jhund, Jaclyn Carberry, Carolyn S.P. Lam, Mikhail N. Kosiborod, Silvio E. Inzucchi, Felipe A. Martinez, Rudolf A. de Boer, Adrian F. Hernandez, Sanjiv J. Shah, Lars Køber, Piotr Ponikowski, Marc S. Sabatine, Magnus Petersson, Anna Maria Langkilde, John J.V. McMurray, Scott D. Solomon
-
Efficacy and safety of the Aria pulmonary endovascular device in pulmonary hypertension Eur. J. Heart Fail. (IF 18.2) Pub Date : 2024-03-14 Christian Gerges, Karl Vollmers, Nika Skoro‐Sajer, Varius Dannenberg, Valerie Hartig, Marc R. Pritzker, John Scandurra, E. Kenneth Weir, Irene M. Lang
-
The salt paradox in heart failure Eur. J. Heart Fail. (IF 18.2) Pub Date : 2024-03-12 Zachary L. Cox, Jeffrey M. Testani
-
Sodium–glucose cotransporter 2 inhibitors influence skeletal muscle pathology in patients with heart failure and reduced ejection fraction Eur. J. Heart Fail. (IF 18.2) Pub Date : 2024-03-12 Nathanael Wood, Sam Straw, Chew W. Cheng, Yu Hirata, Marcelo G. Pereira, Harrison Gallagher, Stuart Egginton, Wataru Ogawa, Stephen B. Wheatcroft, Klaus K. Witte, Lee D. Roberts, T. Scott Bowen
-
Implications of tricuspid regurgitation and right ventricular volume overload in patients with heart failure with preserved ejection fraction Eur. J. Heart Fail. (IF 18.2) Pub Date : 2024-03-11 Karl‐Patrik Kresoja, Sebastian Rosch, Anne Rebecca Schöber, Karl Fengler, Florian Schlotter, Sara Bombace, Paula Sagmeister, Maximilian von Roeder, Tobias Kister, Matthias Gutberlet, Holger Thiele, Karl‐Philipp Rommel, Philipp Lurz
AimsThe aim of this study was to assess the pathophysiological implications of severe tricuspid regurgitation (TR) in patients with heart failure with preserved ejection fraction (HFpEF) by using tricuspid transcatheter edge‐to‐edge repair (T‐TEER) as a model of right ventricular (RV) volume overload relief.Methods and resultsThis prospective interventional single arm trial (NCT04782908) included patients
-
Diuretic use and outcomes in patients with heart failure with reduced ejection fraction: Insights from the VICTORIA trial Eur. J. Heart Fail. (IF 18.2) Pub Date : 2024-03-07 Justin Ezekowitz, Wendimagegn Alemayehu, Frank Edelmann, Piotr Ponikowski, Carolyn S.P. Lam, Christopher M. O'Connor, Javed Butler, Stefano Corda, Ciaran J. McMullan, Cynthia M. Westerhout, Adriaan A. Voors, Robert J. Mentz, Paul W. Armstrong
-
Changes in right ventricular function and clinical outcomes following tricuspid transcatheter edge‐to‐edge repair Eur. J. Heart Fail. (IF 18.2) Pub Date : 2024-03-08 Tetsu Tanaka, Atsushi Sugiura, Refik Kavsur, Can Öztürk, Nihal Wilde, Sebastian Zimmer, Georg Nickenig, Marcel Weber, Johanna Vogelhuber
-
Weight telemonitoring of heart failure versus standard of care in a real‐world setting: Results on mortality and hospitalizations in a 6‐month nationwide matched cohort study Eur. J. Heart Fail. (IF 18.2) Pub Date : 2024-03-07 François Roubille, Grégoire Mercier, Guila Lancman, Hélène Pasche, Sarah Alami, Cécile Delval, Antoine Bessou, Jade Vadel, Amayelle Rey, Stéphanie Duret, Emilie Abraham, Gilles Chatellier, Isabelle Durand Zaleski
-
Blood pressure and intensive treatment up‐titration after acute heart failure hospitalization: Insights from the STRONG‐HF trial Eur. J. Heart Fail. (IF 18.2) Pub Date : 2024-03-06 Matteo Pagnesi, Oscar Alberto Gomez Vilamajó, Alejandro Meiriño, Carlos Alberto Dumont, Alexandre Mebazaa, Beth Davison, Marianna Adamo, Mattia Arrigo, Marianela Barros, Jan Biegus, Jelena Celutkiene, Kamilė Čerlinskaitė‐Bajorė, Ovidiu Chioncel, Alain Cohen‐Solal, Albertino Damasceno, Rafael Diaz, Christopher Edwards, Gerasimos Filippatos, Etienne Gayat, Antoine Kimmoun, Carolyn S.P. Lam, Maria Novosadova
AimsA high‐intensity care (HIC) strategy with rapid guideline‐directed medical therapy (GDMT) up‐titration and close follow‐up visits improved outcomes, compared to usual care (UC), in patients recently hospitalized for acute heart failure (AHF). Hypotension is a major limitation to GDMT implementation. We aimed to assess the impact of baseline systolic blood pressure (SBP) on the effects of HIC versus
-
‘Micro’‐managing heart failure: Restoring that which was lost in translation Eur. J. Heart Fail. (IF 18.2) Pub Date : 2024-03-05 A. Mark Richards, Peipei Wang, Lee Lee Wong
-
Iron replacement therapy in heart failure: Contextualizing the results of the HEART‐FID trial Eur. J. Heart Fail. (IF 18.2) Pub Date : 2024-03-05 Javed Butler, Robert J. Mentz, Adrian F. Hernandez
-
Association of diabetes‐specific heart failure risk score with presence of subclinical cardiomyopathy among individuals with diabetes: A prospective study Eur. J. Heart Fail. (IF 18.2) Pub Date : 2024-03-05 Zainali S. Chunawala, Neil Keshvani, Matthew W. Segar, Kershaw V. Patel, Muhammad Shariq Usman, Vinayak Subramanian, Viraj Raygor, Alvin Chandra, Muhammad Shahzeb Khan, Ambarish Pandey
-
Carbohydrate antigen 125 concentrations across the ejection fraction spectrum in chronic heart failure: The EMPEROR programme Eur. J. Heart Fail. (IF 18.2) Pub Date : 2024-03-05 João Pedro Ferreira, Milton Packer, Naveed Sattar, Javed Butler, Stuart J. Pocock, Stefan D. Anker, Sandra González Maldonado, Marina Panova‐Noeva, Mikhail Sumin, Serge Masson, Faiez Zannad, James L. Januzzi
-
Effect of long‐term tafamidis treatment on health‐related quality of life in patients with transthyretin amyloid cardiomyopathy Eur. J. Heart Fail. (IF 18.2) Pub Date : 2024-03-05 Martha Grogan, Margot K. Davis, Maria G. Crespo‐Leiro, Marla B. Sultan, Balarama Gundapaneni, Franca Stedile Angeli, Mazen Hanna
AimsTo evaluate the effect of long‐term tafamidis treatment on health‐related quality of life (HRQoL) in patients with transthyretin amyloid cardiomyopathy (ATTR‐CM) enrolled in the Tafamidis in Transthyretin Cardiomyopathy Clinical Trial (ATTR‐ACT) and long‐term extension (LTE) study.Methods and resultsWe examined change from baseline in Kansas City Cardiomyopathy Questionnaire overall summary (KCCQ‐OS)
-
Empagliflozin and risk of lower respiratory tract infection in heart failure with mildly reduced and preserved ejection fraction: An EMPEROR‐Preserved analysis Eur. J. Heart Fail. (IF 18.2) Pub Date : 2024-03-05 João Pedro Ferreira, Faiez Zannad, Milton Packer, Gerasimos Filippatos, Stuart J. Pocock, Francisco Vasques‐Nóvoa, Michael Böhm, Javed Butler, Stefan Anker
-
Prevalence of wild‐type transthyretin amyloidosis in a prospective heart failure cohort with preserved and mildly reduced ejection fraction: Results of the Amylo‐VIP‐HF study Eur. J. Heart Fail. (IF 18.2) Pub Date : 2024-03-05 Alwin Tubben, Hendrea S.A. Tingen, Niek H.J. Prakken, Vanessa P.M. van Empel, Thomas M. Gorter, Laura M.G. Meems, Olivier C. Manintveld, Michiel Rienstra, Robert G. Tieleman, Andor W.J.M. Glaudemans, Dirk J. van Veldhuisen, Riemer H.J.A. Slart, Hans L.A. Nienhuis, Peter van der Meer
Transthyretin amyloid cardiomyopathy (ATTR-CM) is an underrecognized fatal disease characterized by extracellular deposition of misfolded transthyretin proteins causing heart failure (HF).1 Previous studies on ATTR-CM prevalence have mostly been performed retrospectively and in selected cohorts.2-4 A recent community screening study found that ATTR-CM, defined in this study by a Perugini grade ≥2 out